WuXi Advanced Therapies, a fully owned subsidiary of WuXi AppTec, has reportedly launched TESSA™ (Tetracycline-Enabled Self-Silencing Adenovirus).

This technology is an advanced process for scalable, transfection-free manufacturing of AAV (adeno-associated virus) at GMP (Good Manufacturing Practice) grade.

Developed by WuXi Advanced Therapies company OXGENE, TESSA™ will accelerate the manufacturing of AAV and substantially reduce the manufacturing costs of gene and cell therapies, allowing global customers to deliver more accessible breakthrough therapeutics to patients as rapidly as possible.

AAV vector is mainly used for the deliverance of gene therapies in disorders like Alzheimer's and hemophilia. Efficient large-scale manufacturing processes are crucial for fulfilling evolving industry requirements. TESSA™ vectors can fulfill the challenges related to the scalability of producing AAV, which has substantial implications for expanding patient access to such advanced therapeutics.

The latest reports back the advantages of this technology. It highlights that in the same volume of manufacturing, TESSA™ vectors generated ten times more AAV in comparison to plasmid-based manufacture, generating sufficient material to treat 10 times the number of patients.

According to the Chief Scientific Officer of WuXi ATU Dr. Ryan Cawood, TESSA™ is a revolutionary system for AAV manufacturing and the advancement of gene and cell therapies to benefit patients.

Dr. Cawood added that the system will improve the scalability, curb process complexity and reduce the costs of manufacturing gene therapies which will enable its global collaborators to develop and provide life-saving gene therapies rapidly to more needy patients.

Being a CTDMO (Contract Testing Development and Manufacturing Organization), the distinct business model of WuXi ATU integrates robust testing abilities with the process development and manufacturing platforms of its advanced therapies like TESSA™ technology for manufacturing AAV and Lenti stable solutions for manufacturing lentiviral.

This enables all biosafety, assay development, product release testing, and viral clearance to be executed in-house, shortening customers’ timelines needed for approving advanced therapies.

Source credit:

https://www.prnewswire.com/news-releases/wuxi-atu-announces-launch-of-tessa-technology-to-improve-scalability-and-accessibility-of-cell-and-gene-therapies-301496614.html